key: cord-1040653-slocvi3r
authors: Sapkal, Gajanan N; Yadav, Pragya D; Ella, Raches; Deshpande, Gururaj R; Sahay, Rima R; Gupta, Nivedita; Mohan, V Krishna; Abraham, Priya; Panda, Samiran; Bhargava, Balram
title: Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2
date: 2021-03-27
journal: J Travel Med
DOI: 10.1093/jtm/taab051
sha: 95347eb36360125e4049556f38bdb40f4abb09ff
doc_id: 1040653
cord_uid: slocvi3r

nan

lineages. This variant carries seventeen mutations in the genome, eight of which were found in spike receptor-binding domain (RBD), mediating the attachment of the virus to the angiotensinconverting enzyme 2 (ACE2) receptor on the surface of human cells. 2 One of these mutations N501Y, at position 501, has asparagine (N) replaced with tyrosine (Y) and has been identified to increase the binding affinity of SARS-CoV-2 to human and murine ACE2. 2 high NAb in convalescent plasma, which was a serious concern. 9 Our study evidently Mutations are expected to occur during viral proliferation in SARS-CoV-2 as witnessed worldwide. Importantly, our study showed that the sera from the vaccine recipients could neutralise the UK-variant strains discounting the uncertainty around potential escape. It was reassuring from the PRNT 50 data generated in our laboratory that the indigenous BBV152/ COVAXIN, following its roll out in the vaccination program, could be expected to work against the new UK-variant. It is unlikely that the mutation 501Y would dampen the potential benefits of the current vaccination program. 

The data that support the findings of this study are available from the corresponding authors upon reasonable request. 

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

Isolation and characterization of VUI97 202012/01, a SARS-CoV-2 variant in travellers from the United Kingdom to India

First isolation of SARS-CoV-2 from clinical samples in India

Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in India

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report medRxiv 2020.12.21

Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients

SARS-CoV-2 escape in vitro from highly neutralizing COVID-19 convalescent plasma